Survey Study About Endoscopy During COVID-19 Pandemic for IBD Doctors


Performance of diagnostic or therapeutic endoscopic procedures in inflammatory bowel disease (IBD) patients can be challenging during a viral pandemic; the main concerns being the safety and protection of patients and health care providers (HCP). The aim of this study is to identify endoscopic practice patterns and outcomes of IBD and coronavirus disease 19 (COVID-19) with a worldwide survey of HCP.

Full Title of Study: “Patterns of Endoscopy During COVID-19 Pandemic: a Global Survey of Interventional Inflammatory Bowel Disease Practice”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: July 15, 2021

Detailed Description

The 20-item survey questionnaire was sent to physician members of the American Society for Gastrointestinal Endoscopy Special Interest Group in Interventional IBD, Chinese IBD Society Endoscopy Interest Group, and the China Crohn's and Colitis Foundation. The data of the survey was collected and analyzed.


  • Other: observation
    • IBD doctors who perform the endoscopy perform the questionnaire

Arms, Groups and Cohorts

  • one group that is IBD endoscopist who perform the endoscopy for IBD patients
    • Complete the questionnaire online

Clinical Trial Outcome Measures

Primary Measures

  • The influence of covid-19 pandemic on endoscopic practice by IBD endoscopist
    • Time Frame: 1 week
    • The incidence of scheduled IBD endoscopies were postponed or cancelled due to the pandemic.

Secondary Measures

  • The incidence of COVID19 in IBD patients who underwent endoscopy
    • Time Frame: 1 week
    • The percentage of IBD patients who underwent endoscopy since the outbreak was tested positive for COVID 19

Participating in This Clinical Trial

Inclusion Criteria

1. Doctors who are involved in the endoscopic treatment of IBD patients; 2. The endoscopist reads and signs an informed consent online. - Exclusion Criteria:

1. Doctors who are not involved in the endoscopic treatment of IBD patients 2. Doctors who need the help of an agent, a witness, or someone else who can not complete the questionnaire independently. 3. Other conditions that the researchers considered unsuitable for inclusion or influenced the participants'ability to complete the study.-

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Second Affiliated Hospital, School of Medicine, Zhejiang University
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Yan Chen, Principal Investigator, 浙江大学医学院附属第二医院

Citations Reporting on Results

Mao R, Liang J, Shen J, Ghosh S, Zhu LR, Yang H, Wu KC, Chen MH; Chinese Society of IBD, Chinese Elite IBD Union; Chinese IBD Quality Care Evaluation Center Committee. Implications of COVID-19 for patients with pre-existing digestive diseases. Lancet Gastroenterol Hepatol. 2020 May;5(5):425-427. doi: 10.1016/S2468-1253(20)30076-5. Epub 2020 Mar 11. No abstract available. Erratum In: Lancet Gastroenterol Hepatol. 2020 Jul;5(7):e6.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.